Clinical Trials Logo

Prostatic Neoplasms clinical trials

View clinical trials related to Prostatic Neoplasms.

Filter by:

NCT ID: NCT04978675 Not yet recruiting - Clinical trials for Prostate Adenocarcinoma

An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer

Start date: October 31, 2021
Phase: Phase 1
Study type: Interventional

This prospective pilot study will assess the feasibility of rh PSMA 7.3 positron emission tomography/magnetic resonance imaging (PET/MRI) scans in detecting prostate cancer that may have come back (recurrent) in patients with increasing levels of prostate-specific antigen (PSA) following prostate surgery (biochemically recurrent). An increase in PSA levels alone does not tell the doctor where the cancer may be or how much cancer there may be. Imaging tests, like a bone scan, MRI, and/or computed tomography, are often performed to help the doctor learn where or how much cancer there is, and how best to treat the cancer. rhPSMA-7.3 is a radioactive tracer agent that when used with PET/MRI imaging may help diagnose and look for the spread of prostate cancer. Prostate-specific membrane antigen (PSMA) is a protein that is expressed in prostate cancer and this agent targets the PSMA molecule. Giving rh PSMA 7.3 during PET/MRI may help doctors better find where the cancer may be spreading and how much of it there is. The results of this trial may also guide in radiotherapy planning.

NCT ID: NCT04978519 Not yet recruiting - Prostate Cancer Clinical Trials

Effectiveness of Cryotherapy Study for Prostate Cancer

Start date: August 1, 2021
Phase: N/A
Study type: Interventional

This is a single-centre prospective, non-randomized trial to investigate the efficacy of cryotherapy in patients with localized prostate cancer.The aim of study is to investigate the safety profile of cryotherapy in the treatment of prostate cancer and to evaluate the oncological control of prostate cancer by means of cryotherapy focal treatment.

NCT ID: NCT04976257 Not yet recruiting - Clinical trials for Prostate Adenocarcinoma

Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion

Start date: August 2, 2021
Phase: Early Phase 1
Study type: Interventional

Prostate-specific membrane antigen (PSMA) agents have shown promise in detecting and treating prostate cancer. Gallium-68-labeled PSMA-11 (68Ga-PSMA-11) is a radioactive agent that binds to prostate cancer cells and can be imaged using positron emission tomography (PET) scanners that detect radioactivity in the body. This early phase I study will use PET to determine if delivering 68Ga-PSMA-11 directly into the prostatic artery (intra-arterial (IA) administration) results in greater uptake in the prostate than delivering 68Ga-PSMA-11 into a vein in the arm (intravenous (IV) administration).

NCT ID: NCT04972097 Not yet recruiting - Prostate Cancer Clinical Trials

Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue

PRESERVE
Start date: September 2021
Phase: N/A
Study type: Interventional

Pivotal study to evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients. This study will assess the safety and effectiveness of the device when used to ablate prostate tissue in intermediate-risk prostate cancer patients.

NCT ID: NCT04967001 Recruiting - Prostatic Neoplasms Clinical Trials

68Ga-PSMA PET in the Prostate Cancer

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

Efficacy of 68Ga PSMA PET / CT in the diagnosis of lymph node metastasis in patients with prostate cancer: a single center prospective randomized controlled trial. To identify and compare the diagnostic efficacy of 68Ga-PSMA PET/CT and mpMRI for lymph nodes in patients with newly diagnosed prostate cancer.

NCT ID: NCT04964271 Not yet recruiting - Prostatic Neoplasms Clinical Trials

Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants.

Start date: July 2021
Phase:
Study type: Observational

This is an exploratory research study with the aim of identifying specific cancer biomarkers in various subtypes of prostate cancer. Blood samples will be collected from 60 participants divided into 40 patients and 20 healthy donors.

NCT ID: NCT04962919 Recruiting - Clinical trials for Prostatic Neoplasms, Castration-Resistant

Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.

LACOG 1818
Start date: January 14, 2020
Phase:
Study type: Observational

Survival outcomes in metastatic prostate cancer in the population Brazilian - analysis of individual characteristics and modalities of treatment in different national health institutions

NCT ID: NCT04962880 Recruiting - Clinical trials for Castration-resistant Prostate Cancer

HRR Prevalence in LatAm PROSPECT Study

PROSPECT
Start date: April 21, 2021
Phase:
Study type: Observational

Determine the prevalence of homologous recombination repair (HRR) gene mutations in participants with mCRPC in Latin America (LatAm) between February 2021 and January 2022.

NCT ID: NCT04962269 Completed - Prostate Cancer Clinical Trials

Application of DWI in Diagnosis of Prostate Cancer

Start date: June 12, 2013
Phase:
Study type: Observational

This study compared the performance of different models of multiple b-value DWI in diagnosing prostate cancer.

NCT ID: NCT04957290 Not yet recruiting - Clinical trials for Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

Start date: August 17, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/Phase 2a, open-label, multicenter study to determine the safety, tolerability, recommended Phase 2 dose (RP2D), efficacy, pharmacokinetics (PK) and pharmacodynamic (PD) properties of idronoxil when rectally administered as a suppository (NOX66) to patients with any solid tumor (Part 1) and patients with metastatic castration-resistant prostate cancer (mCRPC), breast cancer (BC) and non-small-cell lung cancer (NSCLC) (Part 2) who are eligible for low-dose external beam radiotherapy (EBRT) for at least one symptomatic or minimally symptomatic lesion (for the prevention of symptoms).